Table 1.
Demographic and baseline characteristics of COPD patients by training group.
| Characteristic | EET (n = 8) | CET (n = 7) |
|---|---|---|
| Age (years) | 68 ± 2 | 63 ± 2 |
| Height (cm) | 170 ± 3 | 173 ± 2 |
| Weight (kg) | 76 ± 6 | 79 ± 8 |
| BMI (kg/m2) | 26.5 ± 1.9 | 26.7 ± 2.8 |
| FFMI (kg/m2) | 17.5 ± 0.5 | 18.5 ± 1.0 |
| FEV1 (% Pred. Pβ2A) | 36.2 ± 3.7 | 45.8 ± 5.0 |
| FEV1/FVC (% Pred. Pβ2A) | 34.4 ± 3.7 | 37.2 ± 1.7 |
| GOLD Stage II | 1 | 3 |
| GOLD Stage III | 4 | 3 |
| GOLD Stage IV | 3 | 1 |
| Steps per day | 3372 ± 869 | 4271 ± 655 |
Data are presented as means ± SE except disease categories where the values are frequency counts. BMI, Body Mass Index; FFMI, Fat-free mass Index (kg/m2); FEV1, Forced expiratory volume in 1 s; FEV1/FVC, Forced expiratory volume in 1 s over forced vital capacity; GOLD, Global Initiative for Chronic Obstructive Lung Disease, a classification of airflow limitation severity in COPD based on post-bronchodilator FEV1; Stage II (moderate COPD) characterized by FEV1/FVC <70%; 50% <FEV1 <80% predicted; Stage III (severe COPD) characterized by FEV1/FVC <70%; 30% <FEV1 <50% predicted; Stage IV (very severe COPD) characterized by FEV1/FVC <70%; FEV1 <30% predicted. Pβ2A, Post β2Agonist.